Catheter Precision, Inc. (NYSE American: VTAK), a leading U.S.-based developer of advanced medical devices in the cardiac electrophysiology field, has received a significant boost to its intellectual property portfolio. The company announced today that the United States Patent and Trademark Office has issued a notice of allowance for its first U.S. patent for LockeT, a […]
Conduit Pharmaceuticals Inc. (NASDAQ: CDT), a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases, announced today that it has received further patent approval for its lead therapeutic asset targeting autoimmune conditions. The newly granted patent strengthens the company’s intellectual property portfolio and provides added protection for its innovative approach to treating autoimmune
In a landmark step towards strengthening healthcare innovation in Africa, the World Health Organization (WHO) and the Medicines Patent Pool (MPP) have announced strategic support for Nigerian-led advancements in health diagnostics. This collaboration is aimed at fostering local innovation, improving access to affordable diagnostic tools, and enhancing the country’s capacity to respond to pressing public
A research team focused on advancing chimeric antigen receptor (CAR) T-cell therapies has harnessed artificial intelligence tools to streamline data analysis and extract key insights in the field. Their work was highlighted as part of the late-breaking research presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The investigators
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biopharmaceutical firm valued at approximately $324 million, has resolved ongoing patent litigation with Mylan Pharmaceuticals, Inc., a Viatris Inc. subsidiary. Under the terms of the agreement, Heron has granted Mylan the right to begin selling generic alternatives to both drugs starting June 1, 2032. This resolution ends two
Cybin Inc. has been granted U.S. patent number 12,291,499 by the United States Patent and Trademark Office, bolstering its intellectual property portfolio, which now includes over 80 granted patents and more than 230 active applications. CEO Doug Drysdale underscored the significance of strong patent protections in supporting drug innovation and reaffirmed the company’s dedication to
In a significant breakthrough for maternal healthcare, Akums Drugs & Pharmaceuticals has been granted a patent for its extended-release combination formulation of Doxylamine and Pyridoxine, developed to manage nausea and vomiting in pregnancy (NVP). The formulation, which utilizes Akums’ proprietary “tablet-in-tablet” technology, has recently received approval from the Drug Controller General of India (DCGI). Addressing
In a significant ruling that underscores the importance of transparency, reasoned decision-making, and procedural fairness in patent examination, the Calcutta High Court has set aside a refusal order issued by the Patent Office in the case of Takeda Pharmaceutical Co. Ltd. v. Controller of Patents and Designs & Ors. The Court found that the Patent
Starting May 13, 2025, patent applicants will experience a significant change in the timeline for filing continuation and divisional applications with the U.S. Patent and Trademark Office (USPTO). Under the new rule, the window between paying the issue fee and a patent officially issuing will shrink dramatically—from about three weeks to just one week. For
“The needle has moved,” declares Anil Matai, Director General of the Organization of Pharmaceutical Producers of India (OPPI), in a recent podcast interview with Scrip. The statement refers to the substantial changes in India’s intellectual property rights (IPR) regime, which witnessed some critical amendments in the past year. As the representative body for foreign pharmaceutical
